SCHEMBL20179173

SCHEMBL20179173

CC(=O)Oc1ccc(CONC(=O)CCC(Cc2cccc(-c3cccc(C(=O)OC(C)(C)C)c3)c2)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.44
MAPT P10636 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
LTA4H P09960 1/20 0.39
LMNA P02545 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
FOLH1 Q04609 2/20 0.35
RXRA P19793 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
GFER P55789 1/20 0.34
CACNA1B Q00975 1/20 0.34
CTSB P07858 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20179186 0.95 SLC7A5 (0.49) SLC7A5MAPTTDP1LTA4HLMNA
SCHEMBL21570571 0.93 LMNA (0.46) SLC7A5MAPTTDP1LTA4HLMNA
SCHEMBL21577931 0.91 SLC7A5 (0.45) SLC7A5MAPTTDP1LTA4HLMNA
SCHEMBL20168691 0.88 FOLH1 (0.47) SLC7A5LTA4HLMNAGAAFOLH1
SCHEMBL20179243 0.87 FOLH1 (0.42) SLC7A5LTA4HLMNAFOLH1CACNA1B
SCHEMBL20179267 0.86 LTA4H (0.37) SLC7A5LTA4HLMNAGAAHPGD
SCHEMBL21578005 0.85 SLC7A5 (0.50) SLC7A5MAPTTDP1LTA4HLMNA
SCHEMBL24023445 0.85 MAPT (0.42) SLC7A5MAPTTDP1LMNANPSR1
SCHEMBL21577906 0.84 LMNA (0.50) MAPTTDP1LMNAGAAHPGD
SCHEMBL20179268 0.84 LMNA (0.50) MAPTTDP1LMNAGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866394-B2 Prodrugs of hydroxamate-based GCPII inhibitors THE JOHNS HOPKINS UNIVERSTY (US) 2024-01-09 US disclosed
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2021-11-18 US disclosed
WO-2018094334-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS TPI1, HPGDS, GPI SLC7A5 463/4885MAPT 4598/4885TDP1 836/4885
US-11866394-B2 Prodrugs of hydroxamate-based GCPII inhibitors TPI1, HPGDS, GPI SLC7A5 463/4885MAPT 4598/4885TDP1 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.